Skip to content

Investigation of the efficacy of read-through therapy for Nagashima-type palmoplantar keratosis using topical aminoglycoside

Investigation of the efficacy of read-through therapy for Nagashima-type palmoplantar keratosis using topical aminoglycoside - Read-through therapy for Nagashima-type palmoplantar keratosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018677
Enrollment
6
Registered
2015-09-01
Start date
2015-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nagashima-type palmoplantar keratosis

Interventions

The patients apply vaseline or 0.1% gentamicin topically to one of the hands with erythema and hyperkeratosis twice a day for 4 weeks. The patients apply vaseline or 0.1% gentamicin topically to one o

Sponsors

Hokkaido University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: NPPK patients at the Hokkaido University hospital who fulfill the following criteria: 1.Patients aged 1 or older at the time of informed consent. 2.Patients who are homozygous or heterozygous for the mutation c.796C>T in SERPINB7. 3.Patients showing erythema and hyperkeratosis on both hands. 4.Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients who meet exclusion criteria of the drug. 2.Patients with severe complications who need hospitalization. 3.Patients who is considered to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
1.Improvement of skin symptoms such as erythema and hyperkeratosis. 2.Participants' self-assessment of improvement by VAS (Visual Analogue Scale). We evaluate skin symptoms 4 weeks after the treatment.

Countries

Japan

Contacts

Public ContactYuka Ohguchi

Hokkaido University Graduate School of Medicine Department of Dermatology

yu-ohguchi@keb.biglobe.ne.jp011-706-7387

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026